About Nubytide

• Large, growing market - $3.5B+ with 6M US patients

• Differentiated technology - disease modifying

• 12 months from funding to first enrolled patient

• Affordable, easy to administer

Strong IP position

• 8 issued US patents

• 10 issued international patents

Nubytide reduces Aß, markers of inflammation and Tau pathology

Nubytide Mission and Vision

Global
Solution

Disease Modifying

Better Alternative

Reduces Aß Markers

Mission: Make Nubytide available to every patient in the world suffering from Alzheimer's Disease.

Mission: Nubytide is the proactive therapy to delay or stop the onset of the disease to anyone over the age of 65.

Vision: Alzheimer Disease drugs today are monoclonal antibodies which come with higher costs, are harder to administer and are less safe.

Vision: Why Nubytide? Nubytide is a peptide drug which reduces Aß, markers of inflammation and Tau pathology.

Alzheimer's Disease

Alzheimer's Disease is a growing global epidemic

Global Market

• Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias.

• According to the United Nations, that is more than the population of Colombia.

• If breakthroughs are not discovered, this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

• One in three seniors dies with Alzheimer's or related dementia.

Bright Focus Foundation – Alzheimer’s Facts and Figures

U.S. Market

Investor Opportunity

Cenna is Poised to Quickly Move Nubytide Through IND to Exit Phases

Cenna Biosciences Team

Cenna has assembled a team of seasoned biopharmaceutical specialists:

Nazneen Dewji, Ph.D.
Founder, President and CEO

Christine Smith, Ph.D.
CMC

Marwan Sabbagh, MD
Acting CMO
Professor of Neurology

Archie W. Thurston, Jr.,
Ph.D. ADME.
Pharmacology Consultant

Grace Furman, Ph.D.
D.A.B.T., Toxicology
President and CEO,
Paracelcus

Karlene Cork, Ph.D.
Regulatory Affairs

News

Cenna Announces Appointment of David H. Crean to Board of Directors

Press Release - December 19th 2023

Cardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer’s Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego’s 500 Most Influential People for the Last Four Years.

The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Best Stocks - February 7th 2024

Cenna Biosciences, a biopharmaceutical company in La Jolla, California, appointed David H. Crean to its Board of Directors, effective December 12, 2023. Crean, a Managing Partner at Cardiff Advisory LLC, brought over thirty years of experience in mergers & acquisitions, strategic partnerships, and investments in life sciences and healthcare.

Cenna Biosciences Receives NIH NIA Phase II SBIR Award for the Early Clinical Development of Nubytide TM, a First-in-Class, Disease-Modifying Peptide Drug for the Prevention and Treatment of Alzheimer’s Disease

Press Release - September 23rd 2024

Cenna Biosciences Inc., a privately-held biopharmaceutical company based in La Jolla, California, and focused on developing novel treatments for Alzheimer's disease (AD), has been awarded a Phase II SBIR grant of $2.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA), to support the early clinical development of their peptide drug NubytideTM, for the prevention and treatment of AD. AD is a complex disorder for which there are few treatments. There are 55 million people living with AD worldwide, and 6 million in the U.S. alone. The prevalence of AD is expected to grow at a rate of 2.5% per year in the seven major pharmaceutical markets of the world. New medications to prevent the onset, delay progression, or improve symptoms of AD are urgently needed.

Contact Cenna

Email

info@cennabiosciences.com

Phone

(858)-456-0820

Address

505 Coast S Blvd, Suite 407, La Jolla, CA 92037, United States